Suppr超能文献

同步性子宫和卵巢癌的死亡率模式:SEER 注册分析。

Mortality Patterns of Synchronous Uterine and Ovarian Cancers: A SEER Registry Analysis.

机构信息

Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah.

Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.

出版信息

Cancer Epidemiol Biomarkers Prev. 2022 Nov 2;31(11):2038-2045. doi: 10.1158/1055-9965.EPI-22-0587.

Abstract

BACKGROUND

The degree to which uterine cancer metastatic to the ovary is misdiagnosed as synchronous stage I uterine and ovarian cancers is unclear. We sought to determine whether patients with synchronous cancers had mortality patterns similar to either stage IIIA uterine, stage I uterine, or stage I ovarian cancers alone.

METHODS

The Surveillance, Epidemiology, and End Results database was used to compare mortality of patients with synchronous stage I uterine and stage I ovarian cancers versus those with stage IIIA uterine, stage I uterine, or stage I ovarian cancers alone. We calculated age-adjusted mortality hazard ratios (HR) and 95% confidence intervals (CI) accounting for calendar year and grade, adjuvant treatment, grade 1 endometrioid cancers, grade 3 endometrioid cancers, and stage IA cancers.

RESULTS

Among the 9,321 patients, we observed lower age-adjusted mortality in patients with stage I synchronous cancers (n = 937) compared to those with stage IIIA uterine (n = 531; HR, 0.45 95% CI, 0.35-0.58), stage I uterine (n = 6,919; HR, 0.74; 95% CI, 0.60-0.91), and stage I ovarian cancers (n = 934; HR, 0.52; 95% CI, 0.41-0.67). Results were similar after taking into account diagnosis year and grade, and limiting to those receiving adjuvant therapy, grade 1 or grade 3 endometrioid cancers, or stage IA cancers.

CONCLUSIONS

We observed lower mortality for synchronous stage I uterine and ovarian cancers, which was not explained by younger age, earlier stage, lower grade, histology type, or adjuvant therapy.

IMPACT

The possible misdiagnosis associated with clinicopathologic of synchronous uterine and ovarian cancers does not appear to worsen survival on a population level.

摘要

背景

子宫癌转移至卵巢被误诊为同期 I 期子宫和卵巢癌的程度尚不清楚。我们试图确定同期癌症患者的死亡率模式是否与单独的 IIIA 期子宫癌、I 期子宫癌或 I 期卵巢癌相似。

方法

使用监测、流行病学和最终结果数据库比较同期 I 期子宫和 I 期卵巢癌患者与单独 IIIA 期子宫、I 期子宫或 I 期卵巢癌患者的死亡率。我们计算了年龄调整后的死亡率风险比(HR)和 95%置信区间(CI),考虑了日历年度和分级、辅助治疗、I 级子宫内膜样癌、III 级子宫内膜样癌和 IA 期癌症。

结果

在 9321 名患者中,我们观察到同期 I 期癌症患者(n=937)的年龄调整死亡率低于 IIIA 期子宫癌患者(n=531;HR,0.45;95%CI,0.35-0.58)、I 期子宫癌患者(n=6919;HR,0.74;95%CI,0.60-0.91)和 I 期卵巢癌患者(n=934;HR,0.52;95%CI,0.41-0.67)。在考虑诊断年份和分级、限制接受辅助治疗、I 级或 III 级子宫内膜样癌或 IA 期癌症的患者后,结果仍然相似。

结论

我们观察到同期 I 期子宫和卵巢癌的死亡率较低,这不能用年龄较小、分期较早、分级较低、组织学类型或辅助治疗来解释。

影响

与同期子宫和卵巢癌的临床病理相关的可能误诊似乎不会降低人群水平的生存率。

相似文献

1
Mortality Patterns of Synchronous Uterine and Ovarian Cancers: A SEER Registry Analysis.
Cancer Epidemiol Biomarkers Prev. 2022 Nov 2;31(11):2038-2045. doi: 10.1158/1055-9965.EPI-22-0587.
2
[Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Zhonghua Fu Chan Ke Za Zhi. 2018 Dec 25;53(12):816-822. doi: 10.3760/cma.j.issn.0529-567x.2018.12.004.
3
Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer.
Gynecol Oncol. 2017 Dec;147(3):558-564. doi: 10.1016/j.ygyno.2017.09.027. Epub 2017 Oct 4.
5
The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas.
Arch Gynecol Obstet. 2019 Oct;300(4):1045-1052. doi: 10.1007/s00404-019-05288-5. Epub 2019 Sep 14.
6
Clinicopathologic and survival analyses of synchronous primary endometrial and epithelial ovarian cancers.
J Obstet Gynaecol Res. 2015 Nov;41(11):1813-9. doi: 10.1111/jog.12826. Epub 2015 Sep 14.
7
Synchronous dual primary ovarian and endometrial carcinomas.
Int J Gynaecol Obstet. 1993 Dec;43(3):305-12. doi: 10.1016/0020-7292(93)90520-7.
9
Ovarian Conservation and Overall Survival in Young Women With Early-Stage Low-Grade Endometrial Cancer.
Obstet Gynecol. 2016 Oct;128(4):761-70. doi: 10.1097/AOG.0000000000001647.
10
Does synchronous endometrioid endometrial cancer have any prognostic effect on Stage I endometrioid ovarian cancer?
Eur J Obstet Gynecol Reprod Biol. 2016 May;200:113-6. doi: 10.1016/j.ejogrb.2016.03.010. Epub 2016 Mar 17.

引用本文的文献

1
Outcomes and prognostic factors in patients with synchronous endometrial and ovarian cancer.
Arch Gynecol Obstet. 2025 Sep 4. doi: 10.1007/s00404-025-08164-7.
2
A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer.
Clin Cancer Res. 2025 Jun 3;31(11):2230-2240. doi: 10.1158/1078-0432.CCR-24-1763.

本文引用的文献

2
High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
Hum Pathol. 2019 Mar;85:92-100. doi: 10.1016/j.humpath.2018.11.001. Epub 2018 Nov 15.
3
Trends and outcomes of women with synchronous endometrial and ovarian cancer.
Oncotarget. 2018 Jun 19;9(47):28757-28771. doi: 10.18632/oncotarget.25550.
4
Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas.
Gynecol Oncol. 2018 Jul;150(1):92-98. doi: 10.1016/j.ygyno.2018.04.566. Epub 2018 Apr 30.
5
Combination of Scoring Criteria and Whole Exome Sequencing Analysis of Synchronous Endometrial and Ovarian Carcinomas.
Int J Gynecol Cancer. 2018 May;28(4):704-712. doi: 10.1097/IGC.0000000000001227.
6
Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer.
Gynecol Oncol. 2017 Dec;147(3):558-564. doi: 10.1016/j.ygyno.2017.09.027. Epub 2017 Oct 4.
7
Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality.
J Natl Cancer Inst. 2016 Feb 1;108(6):djv428. doi: 10.1093/jnci/djv428. Print 2016 Jun.
8
Clinicopathologic and survival analyses of synchronous primary endometrial and epithelial ovarian cancers.
J Obstet Gynaecol Res. 2015 Nov;41(11):1813-9. doi: 10.1111/jog.12826. Epub 2015 Sep 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验